DOCSLIB.ORG

Genetic/Genomic Testing and Pharmacogenetics (Policy OCA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic/Genomic Testing and Pharmacogenetics (Policy OCA bmchp.org | 888-566-0008 wellsense.org | 877-957-1300 Medical Policy and InterQual® Criteria Genetic/Genomic Testing and Pharmacogenetics Policy Number: OCA 3.727 Version Number: 39 Version Effective Date: 07/01/21 + Product Applicability All Plan Products Well Sense Health Plan Boston Medical Center HealthNet Plan Well Sense Health Plan MassHealth Qualified Health Plans/ConnectorCare/Employer Choice Direct Senior Care Options ◊ Notes: + Disclaimer and audit information is located at the end of this document. ◊ The guidelines included in this Plan policy are applicable to members enrolled in Senior Care Options only if there are no criteria established for the specified service in a Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) on the date of the prior authorization request. Review the member’s product-specific benefit documents at www.SeniorsGetMore.org to determine coverage guidelines for Senior Care Options. Policy Summary The Plan considers genetic and genomic testing to be medically necessary for the diagnosis of genetic disease in children and adults, for the determination of future risk of a suspected disease, for the prediction of drug responses, and/or for the detection of risks of specific diseases to future children when the Plan’s applicable medical policy criteria are met or Plan-adopted InterQual® criteria are met based on the requested genetic test (with InterQual® criteria utilized when criteria are not included in a Plan medical policy). Prior authorization is required. The Plan’s prior authorization requirements are based on the type of genetic test requested, indication(s) for testing, and if the test is ordered, administered, and processed by participating providers and participating laboratories (or non- Genetic/Genomic Testing and Pharmacogenetics + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan. 1 of 111 participating providers and non-participating laboratories). Review the Plan’s Preimplantation Genetic Testing medical policy, policy number OCA 3.726, rather than InterQual® criteria for medical guidelines for preimplantation genetic testing; preimplantation genetic testing is a covered service for some BMC HealthNet Plan members, as specified in the member’s applicable benefit document available at www.bmchp.org. Genetic and genomic testing must comply with applicable Plan reimbursement policies and redirection guidelines. For genetic tests ordered, administered, and processed by participating providers and participating laboratories, Plan prior authorization is required for all molecular and chromosomal genetic testing EXCEPT for a limited number of prenatal genetic screening tests when billed with one (1) of the ICD-10 primary pregnancy diagnosis codes listed in either Category 1 (i.e., procedure codes with the prior authorization requirement waived for members with a Plan-specified, routine pregnancy or high-risk pregnancy ICD-10 primary diagnosis code) or Category 2 (i.e., procedure codes with the prior authorization requirement waived for members with a Plan-specified, high-risk pregnancy ICD-10 primary diagnosis code) of the Applicable Coding section of this policy and when the Plan’s applicable medical policy criteria are met or Plan-adopted InterQual® criteria are met (based on the requested testing). The ICD-10 primary pregnancy diagnosis codes waived from the prior authorization requirement are NOT applicable for Senior Care Options members. Prior authorization is REQUIRED for genetic testing for a pregnant member when the applicable procedure code is NOT listed in Category 1 or Category 2 of the Applicable Coding section. Prior authorization is REQUIRED for ALL molecular and chromosomal genetic testing (when testing is NOT provided to a pregnant member). When genetic tests are order, administered, and/or processed by non-participating providers and/or non-participating laboratories (NOT contracted with the Plan), prior authorization is REQUIRED for all genetic testing, including prenatal genetic screening tests; the list of primary diagnosis codes waived from the prior authorization process would NOT apply to non-participating providers and non- participating laboratories. Biochemical genetic tests used to study molecular markers such as the amount or activity level of proteins and/or steroids to indicate changes to DNA or as biomarkers to determine disease progression, tumor behavior, risk of cancer recurrence, and/or diagnose or treat a genetic condition require prior authorization when specified in the Plan’s Code Look-Up Tools, Prior Authorization Matrix, or a Plan medical policy available at www.bmchp.org for services provided to BMC HealthNet Plan members (including Senior Care Options members) and at www.wellsense.org for testing requested for Well Sense Health Plan members. The Plan recommends that adequate pre-test genetic counseling (including but not limited to preparing the member for possible outcomes of testing including positive results) and post-test genetic counseling be provided by a health care professional with expertise in genetics for all genetic testing conducted with Plan members. Genetic counseling provided to a Plan member (and/or guardian if the member is under the age of 18) should be documented in the member’s medical record and conducted by an appropriately trained practitioner with expertise and experience in genetics, including a provider acting within the scope of the practitioner’s license and practice, clinical geneticist, or genetic counselor. Genetic/Genomic Testing and Pharmacogenetics + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan. 2 of 111 The Plan complies with coverage guidelines for all applicable state-mandated benefits and federally- mandated benefits that are medically necessary for the member’s condition. It will be determined during the prior authorization process if the genetic test is considered medically necessary or experimental and investigational for the requested indication. The Plan’s Medically Necessary medical policy, policy number OCA 3.14, indicates the product-specific definitions of medically necessary treatment, and the Plan’s Experimental and Investigational Treatment medical policy, policy number OCA 3.12, includes the product-specific definitions of experimental or investigational treatment. Plan- adopted InterQual® criteria and the following medical policies include additional prior authorization guidelines for genetic testing and related services: 1. Chromosomal Microarray Analysis for Unexplained Intellectual Disabilities and/or Multiple Congenital Anomalies medical policy, policy number OCA 3.573, includes guidelines for chromosomal microarray analysis (CMA) when used for the diagnosis of an adult or pediatric member with unexplained intellectual disability, developmental delay, symptoms or findings consistent with an autism spectrum disorder, and/or multiple congenital anomalies; applicable InterQual® criteria must be met for CMA for this indication. The Applicable Coding section of policy number OCA 3.573 includes the Plan’s list of high-risk primary pregnancy diagnosis codes and corresponding procedure codes waived for prior authorization for CMA when testing is used for prenatal genetic screening or other pregnancy-related indications such as fetal demise or stillbirth. When CMA is requested to establish a diagnosis and/or prognosis for a member with a malignancy (testing also known as cytogenomic neoplastia microarray analysis) or any other indication not specified above, InterQual® criteria must be met for the requested indication. If no InterQual® criteria are available for the specified indication for CMA testing, applicable medical necessity criteria and coding guidelines must be met in the Medical Policy Statement, Limitations, and Applicable Coding sections of this Genetics/Genomic Testing and Pharmacogenetics medical policy and Plan Medical Director review is required for individual consideration. 2. Drug Screening/Testing for Drugs of Abuse and/or Controlled Substances medical policies, policy number OCA 3.98 for BMC HealthNet members and policy number OCA 3.99 for Well Sense Health Plan members, include guidelines related to specimen validity testing using DNA authentication in conjunction with drug testing for Plan members. 3. Genetic Testing for Fragile X-Associated Disorders medical policy, policy number OCA 3.571, includes the list of primary pregnancy diagnosis codes and corresponding procedure codes waived for prior authorization; applicable InterQual® criteria are used to determine the medical necessity of requested testing. 4. Genetic Testing for Hereditary Thrombophilia medical policy, policy number OCA 3.728, includes the clinical review criteria used to determine medical necessity of requested testing. Genetic/Genomic Testing and Pharmacogenetics + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts
Load more

Recommended publications
  • COMMENTARY Does Transcription by RNA Polymerase Play a Direct Role in the Initiation of Replication?
    Journal of Cell Science 107, 1381-1387 (1994) 1381 Printed in Great Britain © The Company of Biologists Limited 1994 COMMENTARY Does transcription by RNA polymerase play a direct role in the initiation of replication? A. Bassim Hassan* and Peter R. Cook† CRC Nuclear Structure and Function Research Group, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, UK *Present address: Addenbrooke’s NHS Trust, Hills Rd, Cambridge CB2 2QQ, UK †Author for correspondence SUMMARY RNA polymerases have been implicated in the initiation of replication in bacteria. The conflicting evidence for a role in initiation in eukaryotes is reviewed. Key words: cell cycle, initiation, origin, replication, transcription PRIMERS AND PRIMASES complex becomes exclusively involved in the synthesis of Okazaki fragments on the lagging strand. A critical step in this DNA polymerases cannot initiate the synthesis of new DNA process is the unwinding of the duplex. chains, they can only elongate pre-existing primers. The opposite polarities of the two strands of the double helix coupled with the 5′r3′ polarity of the polymerase means that RNA POLYMERASES AND THE INITIATION OF replication occurs relatively continuously on one (leading) REPLICATION IN BACTERIA strand and discontinuously on the other (lagging) strand. The continuous strand probably needs to be primed once, usually The first evidence of a role for RNA polymerase came from at an origin. Nature has found many different ways of doing the demonstration that the initiation of replication in this, including the use of RNA primers made by an RNA poly- Escherichia coli was sensitive to rifampicin, an inhibitor of merase (e.g.
    [Show full text]
  • Antibiotic Resistance by High-Level Intrinsic Suppression of a Frameshift Mutation in an Essential Gene
    Antibiotic resistance by high-level intrinsic suppression of a frameshift mutation in an essential gene Douglas L. Husebya, Gerrit Brandisa, Lisa Praski Alzrigata, and Diarmaid Hughesa,1 aDepartment of Medical Biochemistry and Microbiology, Biomedical Center, Uppsala University, Uppsala SE-751 23, Sweden Edited by Sankar Adhya, National Institutes of Health, National Cancer Institute, Bethesda, MD, and approved January 4, 2020 (received for review November 5, 2019) A fundamental feature of life is that ribosomes read the genetic (unlikely if the DNA sequence analysis was done properly), that the code in messenger RNA (mRNA) as triplets of nucleotides in a mutants carry frameshift suppressor mutations (15–17), or that the single reading frame. Mutations that shift the reading frame gen- mRNA contains sequence elements that promote a high level of ri- erally cause gene inactivation and in essential genes cause loss of bosomal shifting into the correct reading frame to support cell viability viability. Here we report and characterize a +1-nt frameshift mutation, (10). Interest in understanding these mutations goes beyond Mtb and centrally located in rpoB, an essential gene encoding the beta-subunit concerns more generally the potential for rescue of mutants that ac- of RNA polymerase. Mutant Escherichia coli carrying this mutation are quire a frameshift mutation in any essential gene. We addressed this viable and highly resistant to rifampicin. Genetic and proteomic exper- by isolating a mutant of Escherichia coli carrying a frameshift mutation iments reveal a very high rate (5%) of spontaneous frameshift suppres- in rpoB and experimentally dissecting its genotype and phenotypes. sion occurring on a heptanucleotide sequence downstream of the mutation.
    [Show full text]
  • Resistance to Rifampicin: a Review
    The Journal of Antibiotics (2014) 67, 625–630 & 2014 Japan Antibiotics Research Association All rights reserved 0021-8820/14 www.nature.com/ja REVIEW ARTICLE Resistance to rifampicin: a review Beth P Goldstein Resistance to rifampicin (RIF) is a broad subject covering not just the mechanism of clinical resistance, nearly always due to a genetic change in the b subunit of bacterial RNA polymerase (RNAP), but also how studies of resistant polymerases have helped us understand the structure of the enzyme, the intricacies of the transcription process and its role in complex physiological pathways. This review can only scratch the surface of these phenomena. The identification, in strains of Escherichia coli, of the positions within b of the mutations determining resistance is discussed in some detail, as are mutations in organisms that are therapeutic targets of RIF, in particular Mycobacterium tuberculosis. Interestingly, changes in the same three codons of the consensus sequence occur repeatedly in unrelated RIF-resistant (RIFr) clinical isolates of several different bacterial species, and a single mutation predominates in mycobacteria. The utilization of our knowledge of these mutations to develop rapid screening tests for detecting resistance is briefly discussed. Cross-resistance among rifamycins has been a topic of controversy; current thinking is that there is no difference in the susceptibility of RNAP mutants to RIF, rifapentine and rifabutin. Also summarized are intrinsic RIF resistance and other resistance mechanisms. The Journal of Antibiotics (2014) 67, 625–630; doi:10.1038/ja.2014.107; published online 13 August 2014 INTRODUCTION laboratory studies and emerging in patients who received mono- In celebrating the life of Professor Piero Sensi and his discovery of therapy with RIF.
    [Show full text]
  • Plasmid-Based Controls to Detect Rpob Mutations in Mycobacterium Tuberculosis by Quantitative Polymerase Chain Reaction-High-Resolution Melting
    106 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 108(1): 106-109, February 2013 Plasmid-based controls to detect rpoB mutations in Mycobacterium tuberculosis by quantitative polymerase chain reaction-high-resolution melting Joas Lucas da Silva1/+, Gabriela Guimaraes Sousa Leite1, Gisele Medeiros Bastos1, Beatriz Cacciacarro Lucas1, Daniel Keniti Shinohara1, Joice Sayuri Takinami1, Marcelo Miyata1, Cristina Moreno Fajardo1, André Ducati Luchessi1, Clarice Queico Fujimura Leite2, Rosilene Fressatti Cardoso3, Rosario Dominguez Crespo Hirata1, Mario Hiroyuki Hirata1 1Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, SP, Brasil 2Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara, SP, Brasil 3Departamento de Análises Clínicas, Universidade Estadual de Maringá, Maringá, PR, Brasil Quantitative polymerase chain reaction-high-resolution melting (qPCR-HRM) analysis was used to screen for mutations related to drug resistance in Mycobacterium tuberculosis. We detected the C526T and C531T mutations in the rifampicin resistance-determining region (RRDR) of the rpoB gene with qPCR-HRM using plasmid-based controls. A segment of the RRDR region from M. tuberculosis H37Rv and from strains carrying C531T or C526T mutations in the rpoB were cloned into pGEM-T vector and these vectors were used as controls in the qPCR-HRM analysis of 54 M. tuberculosis strains. The results were confirmed by DNA sequencing and showed that recombinant plasmids can replace genomic DNA as controls in the qPCR-HRM assay. Plasmids can be handled outside of bio- safety level 3 facilities, reducing the risk of contamination and the cost of the assay. Plasmids have a high stability, are normally maintained in Escherichia coli and can be extracted in large amounts.
    [Show full text]
  • Transcription in Archaea
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 8545–8550, July 1999 Evolution Transcription in Archaea NIKOS C. KYRPIDES* AND CHRISTOS A. OUZOUNIS†‡ *Department of Microbiology, University of Illinois at Urbana-Champaign, B103 Chemistry and Life Sciences, MC 110, 407 South Goodwin Avenue, Urbana, IL 61801; and †Computational Genomics Group, Research Programme, The European Bioinformatics Institute, European Molecular Biology Laboratory, Cambridge Outstation, Wellcome Trust Genome Campus, Cambridge CB10 1SD, United Kingdom Edited by Norman R. Pace, University of California, Berkeley, CA, and approved May 11, 1999 (received for review December 21, 1998) ABSTRACT Using the sequences of all the known transcrip- enzyme was found to have a complexity similar to that of the tion-associated proteins from Bacteria and Eucarya (a total of Eucarya (consisting of up to 15 components) (17). Subsequently, 4,147), we have identified their homologous counterparts in the the sequence similarity between the large (universal) subunits of four complete archaeal genomes. Through extensive sequence archaeal and eukaryotic polymerases was demonstrated (18). comparisons, we establish the presence of 280 predicted tran- This discovery was followed by the first unambiguous identifica- scription factors or transcription-associated proteins in the four tion of transcription factor TFIIB in an archaeon, Pyrococcus archaeal genomes, of which 168 have homologs only in Bacteria, woesei (19). Since then, we have witnessed a growing body of 51 have homologs only in Eucarya, and the remaining 61 have evidence confirming the presence of key eukaryotic-type tran- homologs in both phylogenetic domains. Although bacterial and scription initiation factors in Archaea (5, 20). Therefore, the eukaryotic transcription have very few factors in common, each prevailing view has become that Archaea and Eucarya share a exclusively shares a significantly greater number with the Ar- transcription machinery that is very different from that of Bac- chaea, especially the Bacteria.
    [Show full text]
  • Sequence Analysis of the Drug‑Resistant Rpob Gene in the Mycobacterium Tuberculosis L‑Form Among Patients with Pneumoconiosis Complicated by Tuberculosis
    MOLECULAR MEDICINE REPORTS 9: 1325-1330, 2014 Sequence analysis of the drug‑resistant rpoB gene in the Mycobacterium tuberculosis L‑form among patients with pneumoconiosis complicated by tuberculosis JUN LU1, SHAN JIANG2, SONG YE1, YUN DENG1, SHUAI MA1 and CHAO-PIN LI3 1Department of Pathogen Biology and Immunology, Anhui University of Science and Technology, Huainan, Anhui 232001; 2Department of Mining Engineering, Huainan Vocational Technical College, Huainan, Anhui 232001; 3Department of Medical Parasitology, Wannan Medical College, Wuhu, Anhui 241002, P.R. China Received June 12, 2013; Accepted February 4, 2014 DOI: 10.3892/mmr.2014.1948 Abstract. The aim of the present study was to investigate the Introduction mutational characteristics of the drug-resistant Mycobacterium tuberculosis L-form of the rpoB gene isolated from patients Tuberculosis is a chronic infectious disease caused by the with pneumoconiosis complicated by tuberculosis, in order to bacterium Mycobacterium tuberculosis, and it remains a reduce the occurrence of the drug resistance of patients and significant public health risk worldwide. Cosmopolitan tuber- gain a more complete information on the resistance of the culosis pestilence has quickly returned due to the misuse of Mycobacterium tuberculosis L-form. A total of 42 clinically antituberculosis drugs and infection with HIV that has been isolated strains of Mycobacterium tuberculosis L-form were apparent since the 1980's (1,2). Since becoming the first elected collected, including 31 drug-resistant strains. The genomic antituberculosis drug, the clinical therapeutic efficacy of RFP DNA was extracted, then the target genes were amplified by has severely degraded due to the appearance of drug-resistant polymerase chain reaction and the hot mutational regions of strains and the L-form mutations of Mycobacterium tubercu‑ the rpoB gene were analyzed by direct sequencing.
    [Show full text]
  • Analysis of the Pcra-RNA Polymerase Complex Reveals a Helicase
    RESEARCH ARTICLE Analysis of the PcrA-RNA polymerase complex reveals a helicase interaction motif and a role for PcrA/UvrD helicase in the suppression of R-loops Inigo Urrutia-Irazabal1, James R Ault2, Frank Sobott2, Nigel J Savery1, Mark S Dillingham1* 1DNA:Protein Interactions Unit, School of Biochemistry, University of Bristol. Biomedical Sciences Building, University Walk, Bristol, United Kingdom; 2Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom Abstract The PcrA/UvrD helicase binds directly to RNA polymerase (RNAP) but the structural basis for this interaction and its functional significance have remained unclear. In this work, we used biochemical assays and hydrogen-deuterium exchange coupled to mass spectrometry to study the PcrA-RNAP complex. We find that PcrA binds tightly to a transcription elongation complex in a manner dependent on protein:protein interaction with the conserved PcrA C-terminal Tudor domain. The helicase binds predominantly to two positions on the surface of RNAP. The PcrA C-terminal domain engages a conserved region in a lineage-specific insert within the b subunit which we identify as a helicase interaction motif present in many other PcrA partner proteins, including the nucleotide excision repair factor UvrB. The catalytic core of the helicase binds near the RNA and DNA exit channels and blocking PcrA activity in vivo leads to the accumulation of R-loops. We propose a role for PcrA as an R-loop suppression factor that helps to minimize conflicts between transcription and other processes on DNA including replication. *For correspondence: [email protected] Competing interests: The Introduction authors declare that no Helicases are conserved proteins found in all kingdoms of life.
    [Show full text]
  • Multiple Rpob Mutants of Mycobacterium Tuberculosis And
    LETTERS 2002;93:92–5. Multiple rpoB demonstrated in vitro for M. smegma- 3. Cisterna R, Cabezas V, Gomez E, Busto C, tis, a surrogate model for M. tubercu- Atutxa I, Ezpeleta C. Community-acquired Mutants of bacteremia. Rev Esp Quimioter. losis, as an increase in reversion 2001;14:369–82. Mycobacterium (mutant to wild-type) rate in rpoB526 4. Calvet HM, Yoshikawa TT. Infections in tuberculosis and or rpsL43 under counterselection by diabetes. Infect Dis Clin North Am. streptomycin or rifampin, respectively 2001;15:407–21. Second-order 5. Bobrow BJ. Incision and drainage of cuta- (4). A correlation between high muta- neous abscesses is not associated with bac- Selection tion rate and antimicrobial resistance teremia in afebrile adults. Ann Emerg Med. was reported for Pseudomonas aerug- 1997;29:404–8. To the Editor: Rad and colleagues inosa isolates from lungs of cystic 6. Lee NY. Hickman catheter–associated bac- recently described variation in some fibrosis patients (5). The mutator P. teremia by Leclercia adecarboxylata and genes involved in DNA repair (mutT2, Escherichia hermannii—a case report. aeruginosa strains resulted from a mutT4, ogt) in Mycobacterium tuber- Korean J Infect Dis. 1999;31:167–70. defective mismatch-repair system (5). 7. de Baere T, Wauters G, Huylenbrock A, culosis strains of different genotypes In M. tuberculosis, mismatch-repair Claeys G, Peleman R, Verschraeger G, et (1). This approach can also be used to genes (mutH, mutL, mutS, and recJ) al.Isolations of Leclercia adecarboxylata investigate developing rifampin from a patient with a chronically inflamed were not found in its genome (6).
    [Show full text]
  • Simultaneous Genotyping and Species Identification Using Hybridization Pattern Recognition Analysis of Generic Mycobacterium DNA Arrays Thomas R
    Downloaded from genome.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press RESEARCH Simultaneous Genotyping and Species Identification Using Hybridization Pattern Recognition Analysis of Generic Mycobacterium DNA Arrays Thomas R. Gingeras,1,7 Ghassan Ghandour,1 Eugene Wang,1 Anthony Berno,1 Peter M. Small,2 Francis Drobniewski,3 David Alland,4 Edward Desmond,5 Mark Holodniy,6 and Jorg Drenkow1 1Affymetrix, Santa Clara, California 95051 USA; 2Division of Infectious Disease, Stanford University, Stanford, California 94305 USA; 3Public Health Laboratory and Medical Microbiology, Kings College School of Medicine and Dentistry, East Dulwich Grove, London SE22 8QF, UK; 4Division of Infectious Disease, Montefiore Medical Center, Bronx, New York 10467 USA; 5Microbial Disease Lab, California Department of Health, Berkeley, California 94704 USA; 6Palo Alto VA Medical Center, Palo Alto, California 94304 USA High-density oligonucleotide arrays can be used to rapidly examine large amounts of DNA sequence in a high throughput manner. An array designed to determine the specific nucleotide sequence of 705 bp of the rpoB gene of Mycobacterium tuberculosis accurately detected rifampin resistance associated with mutations of 44 clinical isolates of M. tuberculosis. The nucleotide sequence diversity in 121 Mycobacterial isolates (comprised of 10 species) was examined by both conventional dideoxynucleotide sequencing of the rpoB and 16S genes and by analysis of the rpoB oligonucleotide array hybridization patterns. Species identification for each of the isolates was similar irrespective of whether 16S sequence, rpoB sequence, or the pattern of rpoB hybridization was used. However, for several species, the number of alleles in the 16S and rpoB gene sequences provided discordant estimates of the genetic diversity within a species.
    [Show full text]
  • Contribution of Phenotypic Heterogeneity to Adaptive Antibiotic Resistance
    Contribution of phenotypic heterogeneity to adaptive antibiotic resistance María Antonia Sánchez-Romero and Josep Casadesús1 Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Seville 41080, Spain Edited by Graham C. Walker, Massachusetts Institute of Technology, Cambridge, MA, and approved November 27, 2013 (received for review August 25, 2013) Antibiotic-resistant isolates of Salmonella enterica were selected The selective value of phenotypic heterogeneity can be envi- on plates containing lethal concentrations of rifampicin, kanamy- sioned in certain cases (6, 20). Furthermore, theoretical analysis cin, and nalidixic acid. The stability of the resistance phenotype supports the view that randomly generated phenotypic diversity was scored after nonselective growth. Rifampicin-resistant (Rifr) can increase the chances of survival when bacterial populations are isolates were stable, suggesting that they had arisen by mutation. subjected to rapid, severe, or complex environmental fluctuations Mutations in the rpoB gene were detected indeed in Rifr mutants. (21, 22). Such bet hedging strategies imply group selection, which In contrast, a fraction of kanamycin-resistant (Kmr) and nalidixic has been considered intrinsically weak in classic population biology acid-resistant (Nalr) isolates showed reduced resistance after non- studies (23). However, models based on game theory suggest that selective growth, suggesting that mechanisms other than muta- strategies that generate phenotypic heterogeneity can provide an tion had contributed to bacterial survival upon lethal selection. evolutionary advantage, despite the fact that they lower the im- Single-cell analysis revealed heterogeneity in expression of the mediate fitness of individual organisms (24–26). Models based on porin gene ompC, and subpopulation separation provided evi- information theory also support the view that bet hedging can be dence that reduced ompC expression confers adaptive resistance advantageous in harsh and changing environments (27).
    [Show full text]
  • Medical Necessity Guidelines: Noncovered Investigational Services Effective: August 18, 2021*
    Medical Necessity Guidelines: Noncovered Investigational Services Effective: August 18, 2021* Prior Authorization Required Yes ☒ No ☐ If REQUIRED, submit supporting clinical documentation pertinent to service request. Applies to: COMMERCIAL Products ☒ Tufts Health Plan Commercial products; Fax: 617.972.9409 ☒ Tufts Health Freedom Plan products; Fax: 617.972.9409 • CareLinkSM – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization TUFTS HEALTH PUBLIC PLANS Products ☒ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); Fax:888.415.9055 ☒ Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans; Fax: 888.415.9055 ☒ Tufts Health RITogether – A Rhode Island Medicaid Plan; Fax: 857.304.6404 ☒ Tufts Health Unify* – OneCare Plan (a dual-eligible product); Fax: 857.304.6304 *The MNG applies to Tufts Health Unify members unless a less restrictive LCD or NCD exists. SENIOR Products • Tufts Health Plan Senior Care Options (SCO), (a dual-eligible product) – Refer to the Tufts Health Plan SCO Prior Authorization List • Tufts Medicare Preferred HMO, (a Medicare Advantage product) – Refer to the Tufts Medicare Preferred HMO Prior Authorization and Inpatient Notification List *For the purposes of this document, this date refers to the date when the list was updated with the addition or deletion of items/services. Please see specific item to determine when that item was placed on noncovered status. According to the Tufts Health Plan Evidence of Coverage (EOC), a treatment or procedure is considered investigative or unproven if reliable evidence shows that the treatment is “under study to determine its safety, efficacy, toxicity, maximum tolerated dose, or its efficacy as compared with a standard means of treatment or diagnosis”.
    [Show full text]
  • The X-Ray Crystal Structure of the Euryarchaeal RNA Polymerase in an Open-Clamp Configuration
    ARTICLE Received 6 Jun 2014 | Accepted 2 Sep 2014 | Published 14 Oct 2014 DOI: 10.1038/ncomms6132 The X-ray crystal structure of the euryarchaeal RNA polymerase in an open-clamp configuration Sung-Hoon Jun1, Akira Hirata1,2, Tamotsu Kanai3, Thomas J. Santangelo4, Tadayuki Imanaka5 & Katsuhiko S. Murakami1 The archaeal transcription apparatus is closely related to the eukaryotic RNA polymerase II (Pol II) system. Archaeal RNA polymerase (RNAP) and Pol II evolved from a common ancestral structure and the euryarchaeal RNAP is the simplest member of the extant archaeal–eukaryotic RNAP family. Here we report the first crystal structure of euryarchaeal RNAP from Thermococcus kodakarensis (Tko). This structure reveals that the clamp domain is able to swing away from the main body of RNAP in the presence of the Rpo4/Rpo7 stalk by coordinated movements of these domains. More detailed structure–function analysis of yeast Pol II and Tko RNAP identifies structural additions to Pol II that correspond to the binding sites of Pol II-specific general transcription factors including TFIIF, TFIIH and Mediator. Such comparisons provide a framework for dissecting interactions between RNAP and these factors during formation of the pre-initiation complex. 1 Department of Biochemistry and Molecular Biology, The Center for RNA Molecular Biology, The Pennsylvania State University, University Park, Pennsylvania 16802, USA. 2 Department of Materials Science and Biotechnology, Graduate School of Science and Engineering, Ehime University, Matsuyama, Ehime 790- 8577, Japan. 3 Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510 Japan. 4 Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, Colorado 80523, USA.
    [Show full text]